Who owns Pharmacyclics?

Key details on Pharmacyclics (Ticker: PCYC)

Who owns Pharmacyclics?

Is PCYC a good stock to own? Find out who bought Pharmacyclics, who sold Pharmacyclics (PCYC) stock, and who holds a large position in Pharmacyclics.

Fund Name Number of Shares Share Valuation As Of
Baker Bros. Advisors 8.74M $875.71M March 31, 2014
T. Rowe Price Associates 6.70M $671.75M March 31, 2014
Ameriprise Financial 3.45M $345.53M March 31, 2014
Vanguard 3.40M $340.73M March 31, 2014
FMR 2.47M $248.00M March 31, 2014
PRIMECAP Management Company 2.38M $238.60M March 31, 2014
SUSQUEHANNA INTERNATIONAL 2.26M $226.96M March 31, 2014
OrbiMed Advisors 2.18M $32.29M Dec. 31, 2011
Capital World Investors^ 1.96M $207.15M Dec. 31, 2013
BlackRock Institutional Trust Company, N.A. 1.64M $164.20M March 31, 2014
FRED ALGER MANAGEMENT 1.46M $146.80M March 31, 2014
GOLDMAN SACHS 1.34M $134.27M March 31, 2014
STATE STREET CORPORATION 1.20M $119.82M March 31, 2014
S.A.C. Capital Advisors 939713 $99.40M Dec. 31, 2013
Barclays 895591 $94.04M Dec. 31, 2013
Columbus Circle Investors 883877 $88.58M March 31, 2014
Janus Capital Management 826635 $82.85M March 31, 2014
ALLIANCEBERNSTEIN 819502 $12.15M Dec. 31, 2011
Charles Schwab Bank 804100 $10.00M March 31, 2013
QVT Financial 772721 $44.65M Dec. 31, 2012
Visium Asset Management 758334 $60.98M March 31, 2013
Franklin Resources 755610 $60.05M June 30, 2013
Bridger Management 750000 $20.82M March 31, 2012
Name Goodman & Company, Investment Counsel 734818 $67.24M March 31, 2014

Who sold Pharmacyclics?

Fund Name Date Sold Number of Shares Sold Share Valuation
BVF Sept. 30, 2011 1.16M $13.70M
Sectoral Asset Management Sept. 30, 2011 745490 $8.82M
Balyasny Asset Management March 31, 2011 1.75M $10.28M
Perceptive Advisors Dec. 31, 2010 2.81M $17.07M
Renaissance Technologies Dec. 31, 2010 890330 $5.41M